Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) President Sells 3,687 Shares of Stock

Key Points

• President Ross Muken executed multiple insider sales under a pre-arranged Rule 10b5-1 plan, selling a total of 16,472 shares (including 3,687 on April 10) to cover tax withholding and raising roughly $78,600, which lowered his stake by about 0.53% to 689,674 shares.
• SOPHiA GENETICS reported a loss (EPS -$0.28) that missed estimates, trades around $4.96 with a market cap near $340M and a 52‑week range of $2.58–$5.70, while analyst coverage is mixed (two Buys, one Sell) with an average price target of $7.00.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) President Ross Muken sold 3,687 shares of the stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.69, for a total value of $17,292.03. Following the completion of the sale, the president directly owned 689,674 shares in the company, valued at approximately $3,234,571.06. This represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Monday, April 13th, Ross Muken sold 4,442 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total value of $21,143.92.
• On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Ross Muken sold 2,786 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total value of $13,484.24.
• On Tuesday, April 7th, Ross Muken sold 2,424 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $11,804.88.
• On Thursday, March 19th, Ross Muken sold 1,183 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $5,666.57.

SOPHiA GENETICS Stock Performance

SOPH stock traded up $0.11 during trading on Tuesday, reaching $4.96. The stock had a trading volume of 148,768 shares, compared to its average volume of 183,135. SOPHiA GENETICS SA has a 52 week low of $2.58 and a 52 week high of $5.70. The stock's 50 day moving average is $4.74 and its two-hundred day moving average is $4.71. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. The firm has a market cap of $339.71 million, a PE ratio of -9.73 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The company had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. As a group, equities analysts anticipate that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $55,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $54,000. Archon Capital Management LLC lifted its stake in shares of SOPHiA GENETICS by 3.4% in the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company's stock valued at $2,061,000 after purchasing an additional 14,342 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of SOPHiA GENETICS by 169.5% in the 4th quarter. Renaissance Technologies LLC now owns 83,000 shares of the company's stock valued at $388,000 after purchasing an additional 52,200 shares during the last quarter. Finally, Polen Capital Management LLC bought a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $102,000. 31.59% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Guggenheim raised their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Finally, BTIG Research reaffirmed a "buy" rating and issued a $7.00 price objective on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, SOPHiA GENETICS presently has an average rating of "Hold" and an average price target of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.